NFKB1 and Sepsis: In the present study, we demonstrated that the pretreatment of levosimendan improved the survival of an experimental model of sepsis with acute liver injury (GalN/LPS model rats) in a dose-dependent manner (Figure 1) and suppressed NF-κB activation in the liver (Figure 2).